ACTRN12622000386730
Recruiting
Phase 1
Therapies to prevent progression of COVID-19, including Ivermectin, Doxycycline, Vitamin C, Vitamin D, and Zinc with or without Famotidine: a randomised placebo-controlled double-blind multi-centre outpatient trial
AProf Dr Karin Ried0 sites300 target enrollmentMarch 4, 2022
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- AProf Dr Karin Ried
- Enrollment
- 300
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •COVID\-19 diagnosis in the preceding 4 days (RAT positive or PCR positive)
- •At least 40 years old
Exclusion Criteria
- •Women who are pregnant, breastfeeding or actively trying to achieve a pregnancy
- •Current hospital inpatient with COVID\-19 related disease
- •Allergy to ivermectin, doxycycline or famotidine
- •Known bleeding disorder
- •Known severe liver disease
- •Diagnosis of Myasthenia Gravis/SLE
- •Consumption of grapefruit juice
- •Ever travelled to countries that are endemic for Loa loa (West and Central Africa – Angola, Cameroon, Central African Republic, Democratic Republic of Congo, Ethiopia, Guinea, Gabon, Republic of Congo, Nigeria and Sudan)
- •Currently on the following medications:
- •oCardiac \- quinidine, amiodarone, diltiazem, verapamil, warfarin
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
International ALLIANCE Study of Therapies to prevent progression of COVID-19, a randomized trialCOVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12620000557932AProf Dr Karin Ried446
Withdrawn
Not Applicable
International ALLIANCE Study of Therapies to prevent progression of COVID-19, a randomized trial - Stage 2COVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12622000309785AProf Dr Karin Ried200
Not yet recruiting
Phase 3
Prevention and treatment for covid-19 associated severe pneumonia in The Gambia: a randomized clinical trial (PaTS-COVID) COVID-19PACTR202101544570971Medical Research Council Unit The Gambia at LSHTM1,200
Active, not recruiting
Phase 2
COVID-19 Prevention of worsening of symptoms in asymptomatic to mild patients by combined use of kakkonto and hochuekkito:Exploratory open-label randomized controlled trialCOVID-19JPRN-jRCTs041200072Ogawa Keiko100
Not yet recruiting
Not Applicable
Cord Blood Therapy to prevent progression of COVID-19 related pneumoniaACTRN12620000478910Monash Health24